Keep up to date
- Press release | 16.07.2018
Univercells raises €16 million in Series B financing round led by Global Health Investment Fund
Investment proceeds will support commercialization of the company’s breakthrough biologics manufacturing technology
- Univercells news | 09.07.2018
Univercells presents preliminary data from its Polio vaccine production platform
Data demonstrates how its micro-facility can achieve a 10-fold reduction in Polio vaccine manufacturing costs
- Univercells news | 25.06.2018
Univercells appoints Christian Borgniet as Chief Operating Officer
Announcing Christian Borgniet, our new COO, bringing to the table his twenty-five years of broad industry experience and knowledge garnered ...
- Univercells news | 16.05.2018
Univercells hits the ground running with new Equipment Design Center
Due to burgeoning development at its Gosselies facility creating the need for more space, Univercells has expanded its activities to ...
- In the press | 01.02.2018
David Shofi appointed Chief Legal Officer at Univercells
Announcing David Shofi, our new Chief Legal Officer and first US-based partner! His 20+ years in IP & general corporate ...
- Press release | 22.01.2018
Univercells to receive €2.4M from Walloon Region for its “Universimilar” program
New endowment to open avenues for the development of Univercells’ innovative antibody manufacturing platform...
- Univercells news | 21.12.2017
Season’s greetings from Univercells
The best is yet to come...
- Press release | 15.12.2017
Univercells secures €3M Series A2 funding
This capital injection will help accelerate the development and commercialization of the company’s technology platforms and innovative solutions
Download Univercells company profile, logo, and picturesPress kit
Belgium Press Inquiries
Univercells - Marketing & Communication firstname.lastname@example.org
International Press Inquiries
Andrew Lloyd & Associates - Juliette Dos Santosjuliette@ala.com
"Disruptive micro-facilities for affordable vaccine manufacturing"
BIO Europe Spring
"Innovative approaches to funding vaccines for emerging pandemics"